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Biglycan is a member of the class I family of small leucine-
rich proteoglycans (SLRPs) (Schaefer and Iozzo 2008). 
The biglycan gene has been mapped to the X chromosome 
(McBride et al. 1990). It encodes for a 42-kDa protein 
core (Bianco et al. 1990) containing leucine-rich repeats 
(LRRs), to which one or two glycosaminoglycan (GAG) 
side chains are covalently bound. The tissue-specific chondroitin-  
or dermatan-sulfate GAG chains of biglycan are attached 
to amino acid residues at the N-terminus of the core   
protein (Choi et al. 1989; Roughley and White 1989). 
There are some indications that biglycan might be a “part-
time” proteoglycan as its non-glycated form has been 
found in aging articular cartilage and intervertebral discs 
(Johnstone et al. 1993; Roughley et al. 1993). Detailed 
structural characteristics of biglycan have been provided 
in recent reviews (Schaefer and Iozzo 2008; Schaefer and 
Schaefer 2010).
Biglycan, which is expressed ubiquitously (Bianco et al. 
1990; Ungefroren et al. 1998), is synthesized as a precursor 
from which an N-terminal propeptide is cleaved off by bone 
morphogenetic protein (BMP) 1 to yield the mature form 
(Scott et al. 2000). Secreted biglycan interacts via its core 
protein or GAG chains with numerous components of the 
extracellular matrix (ECM)—for example, type I, II, III, 
and VI collagen and elastin (Schonherr et al. 1995; 
Hunzelmann et al. 1996; Reinboth et al. 2002; Douglas   
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Summary
Research over the past few years has provided fascinating results indicating that biglycan, besides being a ubiquitous structural 
component of the extracellular matrix (ECM), may act as a signaling molecule. Proteolytically released from the ECM, 
biglycan acts as a danger signal signifying tissue stress or injury. As a ligand of innate immunity receptors and activator of 
the inflammasome, biglycan stimulates multifunctional proinflammatory signaling linking the innate to the adaptive immune 
response. By clustering several types of receptors on the cell surface and orchestrating their downstream signaling events, 
biglycan is capable to autonomously trigger sterile inflammation and to potentiate the inflammatory response to microbial 
invasion. Besides operating in a broad biological context, biglycan also displays tissue-specific affinities to certain receptors 
and structural components, thereby playing a crucial role in bone formation, muscle integrity, and synapse stability at the 
neuromuscular junction. This review attempts to provide a concise summary of recent data regarding the involvement of 
biglycan in the regulation of inflammation and the musculoskeletal system, pointing out both a signaling and a structural role 
for this proteoglycan. The potential of biglycan as a novel therapeutic target or agent for the treatment of inflammatory 
diseases and skeletal muscular dystrophies is also addressed. (J Histochem Cytochem 60:963–975, 2012)
Keywords
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muscular dystrophy, sepsis, Wnt
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et al. 2006; Hwang et al. 2008)—thereby becoming seques-
tered in the ECM of most organs.
Since the discovery of biglycan in developing bone 
almost 30 years ago (Fisher et al. 1983), a multitude of stud-
ies have tried to elucidate the biological role of this proteo-
glycan. Initially, biglycan was considered to be merely a 
static structural component of the ECM. Osteoporosis-like 
phenotype and abnormalities of collagen fibrils observed in 
biglycan-deficient mice initiated a number of investigations 
addressing the mechanisms of biglycan-dependent regula-
tion of bone formation and collagen fiber assembly (Xu 
et al. 1998; Ameye et al. 2002; Corsi et al. 2002; Bi et al. 
2005; Bi et al. 2007; Zhang et al. 2009; Embree et al. 2010). 
Its ability to interact with transforming growth factor (TGF) 
β (Hildebrand et al. 1994); tumor necrosis factor (TNF)-α 
(Tufvesson and Westergren-Thorsson 2002); BMP2, -4, and 
-6 (Chen XD et al. 2004; Mochida et al. 2006); and Wnt-1-
induced secreted protein 1 (WISP1) (Desnoyers et al. 2001) 
established this small leucine-rich proteoglycan (SLRP) as a 
modulator of growth factors and cytokine functions. Recent 
studies discovering biglycan as a signaling molecule 
(Schaefer et al. 2005; Babelova et al. 2009; Moreth et al. 
2010; Berendsen et al. 2011) and a ligand of Toll-like recep-
tors (TLRs)-2 and -4 (Schaefer et al. 2005), P2X7/P2X4 
purinergic receptors (Babelova et al. 2009), low-density 
lipoprotein receptor-related protein 6 (LRP6) (Berendsen   
et al. 2011), or receptor tyrosine kinase MuSK (Amenta et al. 
2012) gave rise to a new paradigm of how this proteoglycan 
regulates a host of biological processes. It firmly established 
biglycan as a part of the innate immune system (Schaefer   
et al. 2005) and a regulator of osteogenesis (Berendsen et al. 
2011; Moreth et al. 2012), synaptic stability (Amenta et al. 
2012), and muscle integrity (Mercado et al. 2006; Rafii   
et al. 2006; Amenta et al. 2011). The observation that biglycan 
is capable of clustering several types of receptors and orches-
trating their signaling (Babelova et al. 2009) further under-
lines the complexity of the biglycan signaling networks.
Reflecting its widespread expression and complex func-
tion, involvement of biglycan in numerous experimental and 
human diseases has been reported (Table 1). Details have 
been summarized in recent reviews on the SLRP family 
(Merline et al. 2009; Iozzo and Schaefer 2010; Kalamajski 
and Oldberg 2010; Schaefer and Schaefer 2010; Theocharis 
et al. 2010; Schaefer 2011; Moreth et al. 2012; Schaefer and 
Iozzo 2012). However, one has to be aware that some of the 
conclusions on the importance of biglycan in certain dis-
eases are exclusively based on histological findings. New 
findings indicate that only unsequestered biglycan is capable 
of acting as a signaling molecule at least in inflammation 
(Schaefer et al. 2005; Babelova et al. 2009). Therefore, the 
amount of biglycan in tissue sections does not necessarily 
reflect its biological effect as it represents mainly biglycan 
that has been sequestered in the ECM, for example, as part 
of the fibrotic scar (Schaefer 2011).
Table 1. Involvement of Biglycan in Selected Experimental and Human Diseases
Disease Species References
Alzheimer disease Mouse Lam et al. 2011
Aortic dissection Mouse, human Bellucci et al. 2007; Heegaard et al. 2007
Asthma Mouse, rat, human Pini et al. 2007; Pinelli et al. 2009; Nihlberg et al. 2010; Venkatesan  
et al. 2012
Atherosclerosis Mouse, rat, human Skalen et al. 2002; Nakashima et al. 2007
Cancer Human Mintz et al. 2005; Coulson-Thomas et al. 2011; Gu et al. 2012; Wang 
B et al. 2011
Diabetes Mouse, rat, human Schaefer et al. 2001; Thompson et al. 2011; Bolton et al. 2012
Duchenne muscular dystrophy Mouse, human Fadic et al. 2006; Mercado et al. 2006; Brandan et al. 2008; Amenta 
et al. 2011
Intervertebral disc disorders Human Brown et al. 2012
Fibrotic liver disease Rat, human Meyer et al. 1992; Krull et al. 1993; Gressner 1994; Hogemann et al. 
1997
Myocardial infarction Mouse, human Campbell et al. 2008; Westermann et al. 2008
Multiple sclerosis Human Mohan et al. 2010
Osteoarthritis Mouse Wadhwa et al. 2005; Embree et al. 2010
Osteoporosis Mouse Xu et al. 1998
Perimyocarditis Mouse Popovic et al. 2011
Fibrotic kidney disease Mouse, rat, human Schaefer et al. 1998; Schaefer et al. 2000; Kuroda et al. 2004; 
Schaefer 2011
Rheumatic arthritis Human Polgar et al. 2003; Sokolove et al. 2012; Antipova and Orgel 2012
Sepsis Mouse Schaefer et al. 2005; Babelova et al. 2009
Systemic lupus erythematosus Mouse, human Moreth et al. 2010Biglycan: A Multivalent Proteoglycan  965
Recent data provide evidence for a crucial role of bigly-
can in the regulation of inflammation, bone growth, and 
muscle development and regeneration. This brief review 
aims to focus on the mechanisms and consequences of big-
lycan interaction with cell surface molecules/receptors in 
those processes to underline the role of biglycan as a multi-
valent, matrix-derived signaling molecule.
Biglycan Signaling in Inflammation
Research over the past few years has provided strong evi-
dence that biglycan in its soluble form acts as danger signal 
bridging the innate and adaptive immune systems (Schaefer 
et al. 2005; Babelova et al. 2009; Moreth et al. 2010; 
Popovic et al. 2011; Schaefer and Iozzo 2012). Following 
tissue stress and injury, biglycan is proteolytically released 
from the extracellular matrix and turns into a host-derived 
non-microbial danger signal (damage-associated molecular 
patterns, DAMPs), which is recognized by innate immunity 
receptors in a manner similar to the function of pathogen-
associated molecular patterns (PAMPs) (Chen GY and 
Nunez 2010). Biglycan core protein can be cleaved by sev-
eral proteolytic enzymes, such as BMP1, matrix metallopro-
teinase (MMP)-2, MMP-3, MMP-13, and Granzyme B 
(Scott et al. 2000; Monfort et al. 2006; Boukpessi et al. 
2008; Calabrese et al. 2011; Boivin et al. 2012). The concept 
that components released from the matrix act as DAMPs, 
activating the immune system during pathogen-mediated 
and sterile inflammation, has been presented in more detail 
in a recent review from our group (Moreth et al. 2012).
Early hints regarding the involvement of biglycan in the 
modulation of the inflammatory process were provided in sev-
eral reports. The expression of biglycan was shown to be ele-
vated in human fibroblasts from granulation tissue, suggesting 
its role in the development of chronic inflammatory lesions 
(Hakkinen et al. 1996). Biglycan levels were also increased in 
experimental pulmonary inflammation (Westergren-Thorsson 
et al. 1993) and bronchial mucosa of asthmatic patients (de 
Kluijver et al. 2005). In a murine model of unilateral ureteral 
obstruction (UUO), the upregulation of biglycan in the renal 
interstitium was followed by macrophage infiltration, indicat-
ing that biglycan might influence the initiation of renal inflam-
mation (Schaefer et al. 2002). In mesangial cells from the renal 
glomerulus, biglycan expression is regulated by nitric oxide 
(NO) (Schaefer et al. 2003). As NO is a crucial proinflamma-
tory mediator in glomerular kidney disease (Pfeilschifter 
2002), involvement of biglycan in inflammatory processes is 
most likely.
Biglycan: An Endogenous Ligand of Innate 
Immunity Receptors
The very first indication that biglycan directly acts as a pro-
inflammatory stimulus came from a study performed in 
murine primary peritoneal macrophages (Schaefer et al. 
2005). This study provided evidence for biglycan-dependent 
signaling, describing the receptors involved, the down-
stream signaling events, and the inflammatory mediators 
subsequently generated (Schaefer et al. 2005). In its soluble 
form, biglycan is able to bind to both TLR2 and -4, trigger-
ing rapid activation of the mitogen-activated protein kinase 
p38, extracellular signal-regulated kinase (Erk), and nuclear 
factor kappa–light-chain enhancer of activated B cells (NF-
κB) and consequently secretion of TNF-α. These signaling 
events were dependent on the MyD88 (myeloid differentia-
tion primary response 88) gene (Fig. 1). Via TLR2/4-
dependent signaling, biglycan triggers the synthesis of 
various chemoattractants for neutrophils and macrophages, 
such as MIP-1α (macrophage inflammatory protein–1α), 
MIP-2, MCP-1 (monocyte chemoattractant protein–1), and 
RANTES (regulated upon activation, normal T cell 
expressed and secreted) (Schaefer et al. 2005; Moreth et al. 
2010) (Fig. 1). Subsequently, the newly attracted macro-
phages, being stimulated by proinflammatory cytokines, 
will in turn start to synthesize biglycan de novo, thereby 
enhancing the inflammatory response (Schaefer et al. 2005; 
Iozzo and Schaefer 2010; Schaefer 2010, 2011; Moreth et al. 
2012). The role of biglycan in inflammation was also 
emphasized in vivo in biglycan-deficient mice, which 
showed longer survival correlated with a lower plasma level 
of TNF-α in lipopolysaccharide (LPS)-induced sepsis com-
pared with wild-type animals (Schaefer et al. 2005).
Besides identifying biglycan as an ECM-derived DAMP, 
these studies have led to new concepts. First, biglycan has to 
be present in its soluble form, because when bound to the 
ECM, biglycan cannot act as a DAMP. Second, the magnitude 
of the biglycan signal can be ramped up rapidly by proteolytic 
liberation from ECM stores without the need for de novo syn-
thesis. Third, both infiltrating macrophages, stimulated by 
proinflammatory cytokines and, at later time points, resident 
cells start to de novo synthesize biglycan at sites of injury or 
damage, in order to drive and shape the inflammatory response 
reaction over time. Fourth, by activating both the receptor for 
the Gram-negative (TLR4) and the Gram-positive (TLR2) 
bacterial response, biglycan, as a signal of tissue damage, acts 
as an amplifier for TLR-induced inflammation.
These initial findings were confirmed by several reports 
describing the coincidence of biglycan overexpression with 
enhanced inflammation and severe tissue injury (Wu et al. 
2007; Leemans et al. 2009; Wang S et al. 2010; Schaefer 
2011) in a TLR-dependent manner (Derbali et al. 2010; 
Moreth et al. 2010; Popovic et al. 2011). Furthermore, a 
number of other ECM components, such as decorin (Merline 
et al. 2011), hyaluronan (Termeer et al. 2002), versican 
(Kim et al. 2009), tenascin-C (Midwood et al. 2009), fibrin-
ogen, and heparan sulfate fragments (Johnson et al. 2002), 
were identified as DAMPs alerting the innate immune sys-
tem to the impending tissue damage. For further details, 966   Nastase et al.
please refer to the review on the role of SLRPs in inflamma-
tion (Moreth et al. 2012).
Biglycan: An Autonomous Trigger of the 
NLRP3 Inflammasome and IL-1b
Further studies indicated that proinflammatory effects of 
biglycan are mediated not only by its interaction with 
TLR2/4 but also by signaling through the NLR family, pyrin 
domain–containing 3 (NLRP3) inflammasome (Babelova et al. 
2009). The NLRP3-inflammasome is a cytoplasmic protein 
complex, containing a Nod-like receptor (NLR), procaspase-1, 
and the adaptor molecule ASC (apoptosis-associated speck-
like protein containing carboxy-terminal CARD). Activation 
of the inflammasome results in the maturation of caspase-1 
with subsequent processing of pro–interleukin-1β (IL-1β) 
into mature IL-1β (Chen GY and Nunez 2010; Tschopp and 
Schroder 2010; Rathinam et al. 2012). Biglycan induces 
secretion of mature IL-1β, a proinflammatory cytokine 
important both in acute and chronic inflammation (Dinarello 
2011), without any need for other costimulatory factors 
(Babelova et al. 2009). The NLRP3-dependent secretion of 
mature IL-1β usually requires two signals. The first signal, 
provided by ligands of TLRs or NOD2, activates NF-κB to 
synthesize pro–IL-1β and NLRP3. The second signal acti-
vates NLRP3/ASC and caspase-1 and leads to cleavage of 
pro–IL-1β (Chen GY and Nunez 2010; Tschopp and Schroder 
2010). Surprisingly, biglycan alone is able to trigger both 
signals autonomously. By binding to and activating TLR2/4 
signaling, biglycan induces the synthesis of pro–IL-1β and 
NLRP3. Based on co-immunoprecipitation data indicating 
the presence of the P2X7 purinergic receptor in the complex 
with TLR2/4, it is tempting to speculate that biglycan 
induces cooperativity between these receptors, thereby 
Figure 1. Biglycan-mediated proinflammatory signaling involves multireceptor crosstalk in macrophages. In macrophages (Φ), soluble 
biglycan interacts with TLR2 and TLR4 and triggers (via MyD88, NF-κB, Erk, and p38) the synthesis of proinflammatory cytokines, such 
as TNF-α and pro–IL-1b as well as various chemoattractants for macrophages and T and B lymphocytes, such as MIP-2, MIP-1α, MCP-1, 
CXCL13, and RANTES. By clustering TLR2/4 with the P2X7 purinergic receptor, biglycan induces the NLRP3/ASC inflammasome and 
caspase-1 activation with subsequent cleavage of pro–IL-1b and release of mature IL-1b. Abbreviations used in the figure: ASC, apoptosis-
associated speck-like protein containing carboxy-terminal CARD; CXCL, C-X-C motif chemokine; Erk, extracellular signal-regulated 
kinase; IL, interleukin; MCP, monocyte chemoattractant protein; MIP, macrophage inflammatory protein; MyD88, myeloid differentiation 
primary response 88; NF-κB, nuclear factor kappa–light-chain enhancer of activated B cells; NLRP3, NLR family, pyrin domain containing; 
p38, mitogen-activated protein kinase p38; RANTES, regulated upon activation, normal T cell expressed and secreted; TNF, tumor necrosis 
factor; TLR, Toll-like receptor.Biglycan: A Multivalent Proteoglycan  967
inducing NLRP3/ASC assembly, which finally leads to the 
activation of caspase-1 and release of mature IL-1β (Babelova 
et al. 2009) (Fig. 1). Both reactive oxygen species (ROS) and 
heat shock protein (HSP) 90 are involved in this process 
(Babelova et al. 2009). Further studies are needed to prove 
this concept and to exclude the independent engagement of 
individual receptors.
All studies so far showed that only intact biglycan is 
capable of triggering proinflammatory signaling both in 
macrophages and in dendritic cells (Schaefer et al. 2005; 
Babelova et al. 2009; Moreth et al. 2010; Popovic et al. 
2011). Therefore, it appears that the combined ability of 
tandem LRRs and GAG side chains allows biglycan to 
interact with different cell surface receptors and their adap-
tor molecules, in order to cluster several types of receptors 
and orchestrate their signaling.
The biglycan-induced inflammasome activation was 
found to be of considerable relevance in vivo in two mouse 
models of sterile renal inflammation (UUO and Murphy 
Roths Large [MRL]/lpr lupus nephritis) and in the proto-
typic pathogen-mediated systemic inflammation of LPS-
induced sepsis (Babelova et al. 2009; Moreth et al. 2010). It 
is conceivable that in sterile inflammatory diseases, soluble 
biglycan acts as an autonomous trigger of inflammation 
using receptor cooperativity between TLR2/TLR4 and the 
P2X7 receptor. In pathogen-mediated inflammation, bigly-
can appears to potentiate the inflammatory response via a 
second TLR, which is not involved in pathogen sensing 
(e.g., via a TLR2 in Gram-negative pathogen response).
In fact, recent reports indicated that biglycan and decorin 
are present in their soluble form in the extracellular space 
under sterile and pathogen-mediated inflammatory condi-
tions (Moreth et al. 2010; Merline et al. 2011). The source 
of circulating biglycan still remains a matter of speculation. 
Probably both de novo synthesized and matrix-derived big-
lycan contribute to the circulating pool of this proteoglycan. 
De novo synthesis of biglycan can be triggered in various 
cell types by TGFβ (Border et al. 1990; Ungefroren and 
Krull 1996; Mozes et al. 1999). In macrophages, IL-6 and 
IL-1β have been shown to stimulate the synthesis of bigly-
can (Schaefer et al. 2002; Schaefer et al. 2005). It is con-
ceivable that rapid generation of biglycan may exceed the 
capacity of the ECM to sequester this proteoglycan, causing 
some spillover of biglycan into the circulation. Furthermore, 
sequestered biglycan might be liberated from the ECM by 
proteolytic enzymes secreted from infiltrating or resident 
cells in response to tissue stress or damage.
Biglycan Signaling: A Link between Innate 
and Adaptive Immunity
Recent studies established biglycan signaling as an impor-
tant link between the innate and adaptive immune systems 
(Moreth et al. 2010; Popovic et al. 2011). In macrophages 
and dendritic cells, soluble biglycan induces the expression 
of CXCL13 (C-X-C motif chemokine 13) by signaling 
through TLR2/4 (Moreth et al. 2010). CXCL13 is the major 
chemoattractant for B cells and an important biomarker for 
disease activity of systemic lupus erythematosus (Fig. 1). In 
patients with lupus nephritis (LN) and in lupus-prone mice, 
enhanced plasma levels of biglycan correlate with the abun-
dance of circulating CXCL13 and the extent of albumin-
uria. In lupus-prone mice, the knockout or overexpression 
of the biglycan gene was clearly associated with CXCL13 
expression, number of B cells in the kidney, and organ 
damage and albuminuria (Moreth et al. 2010). It is conceiv-
able that biglycan, by attracting B cells to non-lymphoid 
organs, promotes the development of tertiary lymphoid 
tissue and aggravation of the disease. Moreover, by overex-
pressing soluble biglycan in mice lacking TLR2 and TLR4, 
the first direct proof for the in vivo involvement of both 
TLRs in biglycan-mediated signaling was provided. 
Interestingly, soluble biglycan particularly facilitated the 
recruitment of B1 lymphocytes, which are involved in the 
early, T-cell–independent immune response (Moreth et al. 
2010). Thus, these findings underline the role of biglycan 
as a potent inducer of inflammation, which can rapidly trig-
ger autoantibody production without T-cell involvement.
However, biglycan-dependent regulation of adaptive 
immunity is not limited to the regulation of B lymphocytes. 
By signaling via TLR2/4, soluble biglycan also regulates 
the behavior of T lymphocytes. It induces the synthesis of 
RANTES, thereby recruiting T lymphocytes into the kidney 
(Moreth et al. 2010) (Fig. 1). In addition, by signaling 
through both TLRs and their adaptor molecules MyD88 and 
TRIF (TIR-domain-containing adaptor-inducing interferon 
β), biglycan plays a crucial role in MHC I– and MHC II–
restricted T-cell cross-priming. Biglycan-mediated stimula-
tion of TLR4 signaling is particularly important for MHC 
II-dependent, antigen-specific T-cell activation (Popovic 
et al. 2011). Accordingly, in a model of experimental auto-
immune perimyocarditis (EAP), TLR4-dependent biglycan 
signaling amplified cardiomyocyte antigen presentation to 
prime T cells (Popovic et al. 2011). Beside the above- 
mentioned direct evidence for the impact of biglycan on 
bridging the innate and adaptive immune response, several 
further implications suggest an even wider impact of bigly-
can on both immune systems (Kikuchi et al. 2000; Kitaya 
and Yasuo 2009; Sjoberg et al. 2009). Details are summa-
rized in a recent review (Moreth et al. 2012).
Taking all these findings into consideration, the afore-
mentioned studies emphasize the prospect of biglycan as a 
therapeutic target for intervention in sterile and pathogen-
mediated inflammation. Thus, further studies concerning 
the intricate interactions between biglycan and innate 
immune receptors would most likely reveal significant 
insights for the development of new drugs for the treatment 
of biglycan-mediated inflammatory diseases.968   Nastase et al.
Biglycan Signaling in Bone 
Formation
A role for biglycan in the growth of bone was suspected 
based on the observation that female patients with Turner 
syndrome, lacking the second X chromosome, have a 
shorter stature and abnormally low expression of biglycan, 
contrary to patients with supernumerary X chromosomes 
(Ameye and Young 2002). By the observation that biglycan-
deficient mice display an osteoporosis-like phenotype, 
biglycan was discovered to be the first non-collageneous 
matrix component found in bone, being a regulator of bone 
formation and mass (Xu et al. 1998; Young et al. 2002). 
Identification of the underlying molecular mechanisms for 
developing this phenotype in biglycan-deficient mice has 
been of particular interest in the past years (Wadhwa et al. 
2004; Young et al. 2006; Bi et al. 2007; Wadhwa et al. 
2007; Embree et al. 2010; Berendsen et al. 2011).
It was shown that with increasing age, biglycan-deficient 
mice produce lower numbers of bone marrow-derived stro-
mal cells (BMSC-osteogenic precursors). In addition, the 
response of BMSCs to TGFβ also becomes impaired, sug-
gesting a possible role of BMP signaling in the develop-
ment of this phenotype (Ameye and Young 2002; Chen XD 
et al. 2002). Indeed, biglycan was shown to modulate BMP4 
(bone morphogenetic protein 4)-mediated osteoblast differ-
entiation in murine calvarial cells by controlling Smad1 
phosphorylation and Cbfa1 (core binding factor α1) expres-
sion (Chen XD et al. 2004) (Fig. 2). Another study also con-
firmed the role of biglycan in osteoblast differentiation and 
subsequent matrix mineralization through the BMP4 signal-
ing pathway (Parisuthiman et al. 2005). An opposite effect 
of biglycan in BMP4 signaling was shown in the context of 
embryonic development. Microinjection of biglycan mRNA 
into Xenopus embryos inhibits BMP4 activity and affects 
embryonic development. At the molecular level, biglycan 
Figure 2. Network of biglycan signaling in osteoblast differentiation and stabilizing role of biglycan in skeletal muscle. In bone, biglycan 
stimulates the BMP/TGFb pathways, leading to the transcription of osteoblast-related genes and osteoblast differentiation. By binding 
to the Wnt3a ligand and its receptor LRP6, biglycan potentiates the Wnt/b-catenin signaling pathway, thereby further contributing to 
osteoblast differentiation. In skeletal muscle, biglycan associates with the dystrophin-glycoprotein complex and contributes to its stability 
and to muscular integrity. For further details, refer to the text. Abbreviations used in the figure: BMP, bone morphogenic protein; BMP-R, 
bone morphogenic protein receptor; Cbfa1, core binding factor α1; FZ, Frizzled receptor; LRP, low-density lipoprotein receptor–related 
protein; nNOS, neuronal nitric oxide synthase; TCF, lymphoid enhancer binding factor/T-cell–specific factor; TGFb, transforming growth 
factor b; TGFb-R, transforming growth factor b receptor; Wnt, Wingless and Int.Biglycan: A Multivalent Proteoglycan  969
binds to BMP4 and chordin, a negative regulator of BMP4, 
increasing the binding efficiency between the aforemen-
tioned proteins, thereby blocking BMP4 activity (Moreno 
et al. 2005). Besides BMP4, in vitro binding assays showed 
that biglycan interacts with other BMPs, such as BMP2 and 
6. Biglycan is able to directly bind BMP2 and its receptor, 
ALK6 (also known as BMP-RIB), to stimulate BMP2-
dependent osteoblast differentiation (Moreno et al. 2005). 
Moreover, de-glycanation of biglycan increases its positive 
effect on BMP2 signaling and function (Miguez et al. 2011).
However, the signaling role of biglycan in bone is not 
restricted to interactions with BMPs. Biglycan is also able 
to activate the canonical Wnt/β-catenin signaling (Fig. 2). 
The activation of the Wnt/β-catenin pathway involves the 
binding of Wnt ligand to the Frizzled receptor (FZ) and its 
coreceptor, LRP6, increasing the stability of β-catenin in 
the cytosol and promoting its translocation into the nucleus. 
Consequently, β-catenin activates LEF1/TCF (lymphoid 
enhancer-binding factor/T-cell-specific factor)-related gene 
transcription (Berendsen et al. 2011) (Fig. 2). Biglycan 
directly binds to the Wnt ligand and LRP6 through its pro-
tein core. The lack of biglycan led to impaired Wnt-induced 
LRP6 phosphorylation and LEF1/TCF-mediated transcrip-
tional activity in calvarial cells. The same study showed that 
in vivo, biglycan regulates WISP1 expression during bone 
formation in a fracture-healing model (Berendsen et al. 
2011). Nevertheless, further studies are needed to elucidate 
the molecular mechanism, through which biglycan regu-
lates the Wnt pathway in more detail.
Based on findings that biglycan directly binds to WISP1 
protein (Desnoyers et al. 2001) and that WISP1 mRNA colo-
calizes with biglycan during mineralization in vivo (French 
et al. 2004; Inkson et al. 2009), it has been suggested that this 
interaction plays a role in the differentiation and proliferation 
of osteogenic cells. Briefly, the matrix component biglycan 
stimulates the bone formation process through a dual-signal-
ing mechanism: BMP/TGFβ signaling and the canonical 
Wnt/β–catenin-induced pathway (Fig. 2). Therefore, bigly-
can might be a promising drug target in bone-related diseases 
caused by defects in these signaling pathways.
Muscular Dystrophies: Regulatory 
Mechanisms of Biglycan and Novel 
Therapeutic Options
In early studies, biglycan was shown to be expressed in 
muscle tissue (Bianco et al. 1990; Bosse et al. 1993), but it 
took almost a decade until a study was published on the role 
of biglycan in muscle, which demonstrated that biglycan 
binds to dystroglycan and that its expression level is 
increased in the muscle of mdx mice, a model of Duchenne 
muscular dystrophy (DMD) (Bowe et al. 2000). Later, 
increased levels of biglycan were also found in skeletal 
muscle of DMD patients (Zanotti et al. 2005; Fadic et al. 
2006).
DMD is a lethal X-linked recessive disorder caused by 
mutations in the dystrophin gene that lead to a shift in the 
reading frame and an early stop codon, causing the loss or 
reduction in the synthesis of the dystrophin protein, which 
finally prevents the assembly of the dystrophin-glycopro-
tein complex (DGC) (Ameen and Robson 2010). The DGC 
is a large protein complex including both cytoplasmic com-
ponents (dystrophin, syntrophins, dystrobrevins, and neuro-
nal nitric synthase [nNOS]) and transmembrane components 
(dystroglycan and sarcoglycans) (Brandan et al. 2008). 
Lack of this complex renders the muscle fibers extremely 
vulnerable to damage, which occurs during muscle contrac-
tion. This gives rise to repeated cycles of muscle damage 
and regeneration as the organism tries to cope with this con-
dition but finally results in depletion of regenerative myo-
genic cells and loss of regenerative ability (Brussee et al. 
1997; Luz et al. 2002). The most commonly used model of 
DMD is the mdx mouse, which has a nonsense mutation in 
exon 23 of the dystrophin gene (Zhou and Lu 2010).
Biglycan has been shown to bind to several components 
of the DGC: α-dystroglycan (Bowe et al. 2000) as well as α- 
and γ-sarcoglycan (Rafii et al. 2006). Although O-linked gly-
cosylation of α-dystroglycan is needed for its interaction with 
other proteoglycans (agrin, laminin, perlecan), the interac-
tion with biglycan occurs between the GAG chains of big-
lycan and the carboxy-terminal one-third of α-dystroglycan, 
indicating that α-dystroglycan is able to bind two molecules 
of biglycan simultaneously (Bowe et al. 2000). By contrast, 
biglycan interacts with α- and γ-sarcoglycan but not with 
β- or δ-sarcoglycan through distinct parts of its protein core 
(Rafii et al. 2006).
These interactions with three distinct components of the 
DGC (Fig. 2) led to the idea that biglycan is associated with 
this complex. As proof of this concept, biglycan was shown 
to co-immunoprecipitate with α-, β-, γ-sarcoglycan as well as 
with dystrophin, even though it did not directly bind to dys-
trophin or β-sarcoglycan. Therefore, co-immunoprecipitation 
with these two proteins was concluded to be a result of 
biglycan association to the assembled DGC. Moreover, 
biglycan selectively regulates the expression of α- and 
γ-sarcoglycan, with expression of these two proteins being 
reduced in muscle from young biglycan-null mice but not 
adults (Rafii et al. 2006).
In addition, a further study on biglycan-null mice showed 
that biglycan also regulates the expression and sarcolemmal 
localization of other DGC components: dystrobrevin, syn-
throphin, and nNOS. Biglycan-null mice have a mildly dys-
trophic phenotype and present several defects in the 
localization of DGC components. α-Dystrobrevin-1 and -2 
have a selective reduction in their localization at the sarco-
lemma. On the other hand, nNOS is also decreased tran-
scriptionally in null mice. Different types of synthrophins 970   Nastase et al.
are affected differently by a lack of biglycan, with the larg-
est effect on β1-syntrophin. Remarkably, sarcolemmal 
localization of these components in biglycan-null mice can 
be restored by the injection of purified biglycan core protein 
into muscle (Mercado et al. 2006). Thus, biglycan seems to 
be capable of regulating multiple components of the DGC 
(Fig. 2) and shows some potential as a therapeutic agent in 
the treatment of muscle dystrophy.
In a study performed in mdx mice, a therapeutic role for 
biglycan has indeed been proven (Amenta et al. 2011). 
Absence of biglycan was shown to decrease the sarcolem-
mal expression of utrophin, the autosomal homologue of 
dystrophin, whereas injection of recombinant human bigly-
can in biglycan-null mice increased the expression of utro-
phin. A similar effect was shown in mdx mice, where 
injection of biglycan could increase the expression of utro-
phin in muscle 2.5-fold, associated with an increase in 
γ-sarcoglycan, β2-syntrophin, and nNOS levels at the sar-
colemma. Furthermore, injection of biglycan in mdx mice 
ameliorated dystrophic symptoms, depending on the pres-
ence of utrophin (Amenta et al. 2011). Importantly, the 
therapeutic effects of biglycan in an experimental model of 
DMD are mediated by the protein core. Therefore, proin-
flammatory effects of biglycan are not to be expected, as 
intact biglycan encompassing the GAG side chains is 
needed for signaling through TLR2 and TLR4.
Besides its role in the assembly of the DGC, biglycan 
has also been shown to be upregulated in regenerating skel-
etal muscle, although the presence of biglycan is not essen-
tial for muscle regeneration and is possibly compensated 
for by decorin in biglycan-null mice (Casar et al. 2004). 
Through its binding to TGFβ, biglycan could also poten-
tially modulate processes such as proliferation, migration, 
and differentiation (Brandan et al. 2008). In addition, bigly-
can expression was recently localized to the neuromuscular 
junction, whereas mature biglycan-null mice have abnor-
mal neuromuscular synapses and have a reduced synaptic 
expression of the receptor tyrosine kinase MuSK. 
Consequently, it was shown that biglycan serves as a ligand 
for MuSK, regulates agrin-induced MuSK phosphorylation, 
and is necessary for stabilizing agrin-induced acetylcholine 
receptor clusters. Taken together, these results suggest that 
biglycan also plays an important role in the stability of neu-
romuscular synapses (Amenta et al. 2012).
Future Perspectives
Research over the past few years has resulted in consider-
able progress in our understanding of the biology of bigly-
can. Particular attention was focused on the interaction 
between biglycan and various cell surface binding partners, 
some of them being signaling receptors. The initial concept 
that soluble biglycan acts a signaling molecule became 
much more complex when new data showed that biglycan 
is capable of clustering different types of receptors on the 
cell surface, thereby orchestrating their downstream signal-
ing events.
Current knowledge on biglycan in inflammation, bone 
development, and muscular dystrophy summarized in this 
review suggests that besides general effects of this proteo-
glycan acting as a danger signal in matrix stress or injury, 
other effects are strongly tissue specific. There is good evi-
dence demonstrating the tissue-specific effects of biglycan 
in muscular dystrophy and in bone formation. However, it 
is conceivable that in contrast to muscle-specific associa-
tion of biglycan with the dystrophin-glycoprotein complex, 
its interactions with BMP/TGFβ and Wnt/β-catenin path-
ways may play an important role not only in bone formation 
but also in fibrotic disorders. Thus, new studies in various 
tissues under physiological and pathological conditions 
should expand the current knowledge.
The challenges ahead lie in transferring basic research on 
biglycan into the clinic. Both in sterile and pathogen-induced 
inflammatory conditions, the interaction of biglycan with 
innate immunity receptors might represent a promising tar-
get for the development of new anti-inflammatory therapies. 
Possible strategies for neutralizing the proinflammatory 
effects of biglycan might include neutralizing antibodies, 
truncated molecules, or chemically synthesized small mole-
cules. On the other hand, biglycan by itself could serve as a 
promising treatment in some skeletal muscular dystrophies. 
A more detailed understanding of the physicochemical and 
structural properties of the binding sites through which big-
lycan interacts with its various binding partners will be a 
critical component of this effort.
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